iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
iTeos Therapeutics (ITOS) announced upcoming presentations of preclinical, translational, and clinical data for inupadenant at the ESMO Immuno-Oncology Congress 2024 in Geneva. The presentations will include results from the Phase 2 A2A-005 trial studying inupadenant combined with platinum-doublet chemotherapy in post-immunotherapy metastatic non-small cell lung cancer (NSCLC) patients. The data will be presented through two mini oral presentations and one poster session on December 12, 2024, focusing on inupadenant's effects on humoral responses and its combination with chemotherapy in NSCLC patients.
iTeos Therapeutics (ITOS) ha annunciato che presenterà prossimamente dati preclinici, traslazionali e clinici per inupadenant al Congresso ESMO di Immuno-Oncologia 2024 a Ginevra. Le presentazioni includeranno i risultati del trial di Fase 2 A2A-005 che studia l'inupadenant combinato con chemioterapia a base di platino in pazienti con cancro ai polmoni non a piccole cellule (NSCLC) metastatici dopo immunoterapia. I dati saranno presentati attraverso due presentazioni orali brevi e una sessione di poster il 12 dicembre 2024, focalizzandosi sugli effetti di inupadenant sulle risposte umorali e sulla sua combinazione con la chemioterapia nei pazienti NSCLC.
iTeos Therapeutics (ITOS) anunció próximas presentaciones de datos preclínicos, traslacionales y clínicos para inupadenant en el Congreso ESMO de Inmuno-Oncología 2024 en Ginebra. Las presentaciones incluirán resultados del ensayo de Fase 2 A2A-005 que estudia inupadenant en combinación con quimioterapia con doblete de platino en pacientes con cáncer de pulmón no microcítico (NSCLC) metastásico después de la inmunoterapia. Los datos se presentarán a través de dos presentaciones orales breves y una sesión de póster el 12 de diciembre de 2024, centrándose en los efectos de inupadenant en las respuestas humorales y su combinación con quimioterapia en pacientes con NSCLC.
iTeos Therapeutics (ITOS)는 2024년 제네바에서 열리는 ESMO 면역종양학 컨그레스에서 inupadenant에 대한 전임상, 번역, 임상 데이터를 발표할 예정이라고 발표했습니다. 발표는 면역요법 후 전이성 비소세포 폐암(NSCLC) 환자에서 플래티넘 더블렛 화학요법과 병행하여 inupadenant를 연구한 2상 A2A-005 시험의 결과를 포함합니다. 데이터는 2024년 12월 12일 두 개의 미니 구두 발표와 하나의 포스터 세션을 통해 발표되며, NSCLC 환자에서 inupadenant의 면역 반응과 화학요법과의 조합에 대한 영향을 집중적으로 다룰 것입니다.
iTeos Therapeutics (ITOS) a annoncé des présentations à venir de données précliniques, translationnelles et cliniques pour inupadenant au Congrès ESMO sur l'immuno-oncologie 2024 à Genève. Les présentations incluront des résultats de l'
iTeos Therapeutics (ITOS) gab bekannt, dass sie beim ESMO Immuno-Oncology Congress 2024 in Genf bevorstehende Präsentationen zu präklinischen, translationalen und klinischen Daten für inupadenant ankündigen wird. Die Präsentationen umfassen Ergebnisse aus der Phase 2 A2A-005 Studie, die inupadenant in Kombination mit platinhaltiger Doppeltchemotherapie bei post-immuntherapeutischen metastatischen nicht-kleinzelligen Lungenkrebs (NSCLC) Patienten untersucht. Die Daten werden am 12. Dezember 2024 in zwei Mini-oral-Präsentationen und einer Poster-Sitzung präsentiert, wobei der Schwerpunkt auf den Auswirkungen von inupadenant auf die humoralen Antworten und seiner Kombination mit Chemotherapie bei NSCLC-Patienten liegt.
- Phase 2 clinical trial data selected for presentation at major oncology conference
- Multiple presentation formats (mini oral and poster) suggesting comprehensive data package
- None.
WATERTOWN, Mass. and GOSSELIES, Belgium, Oct. 24, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that preclinical, translational, and clinical data from inupadenant will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2024, being held December 11-13, 2024 in Geneva, Switzerland. The clinical and translational data from the dose escalation portion of A2A-005, the Phase 2 trial assessing inupadenant and platinum-doublet chemotherapy in post-immunotherapy metastatic non-small cell lung cancer (NSCLC) patients, will be presented as mini oral presentations. Preclinical data from inupadenant will be presented in the poster session.
Mini Oral Presentation Details
Title: The A2AR Antagonist Inupadenant Promotes Humoral Responses in Patients
Abstract Number: 174MO
Session Title: Mini Oral Session 1
Date / Time: December 12, 2024 at 9:24 am CEST
Title: Inupadenant Combined with Chemotherapy in Patients with Non-Squamous NSCLC Progressing On or After Immune Checkpoint Inhibitor Therapy: Results from Dose-Finding Part of the A2A-005 Trial
Abstract Number: 120MO
Session Title: Mini Oral Session 2
Date / Time: December 12, 2024 at 14:55 pm CEST
Poster Presentation Details
Title: The A2AR Antagonist Inupadenant Promotes Humoral Responses in Preclinical Models
Abstract Number: 48P
Session Title: Poster Display Session
Date / Time: December 12, 2024 at 12:30 pm CEST
ESMO-IO indicates that all regular abstracts will be published on the ESMO-IO website on Thursday, December 5, 2024 at 00:05 am CEST.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.
About Inupadenant (EOS-850)
Inupadenant is a next-generation small molecule antagonist targeting adenosine A2A receptor (A2AR), the primary receptor on immune cells whose activation by adenosine suppresses innate and adaptive immune cell responses leading to inhibition of antitumor responses. Optimized for potency, high selectivity of A2AR, and activity at high adenosine concentrations in solid tumors, inupadenant is uniquely designed with its insurmountable profile to inhibit the ATP-adenosine pathway and has the potential for enhanced antitumor activity as compared to other A2AR antagonists in clinical development. The therapeutic candidate is in Phase 2 development.
Internet Posting of Information
iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.
For further information, please contact:
Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
FAQ
What will iTeos Therapeutics (ITOS) present at ESMO-IO Congress 2024?
When will iTeos Therapeutics (ITOS) present their inupadenant Phase 2 trial results?
What is the focus of iTeos Therapeutics' (ITOS) A2A-005 trial?
